Houston Mark, Chen Chen, D'Adamo Christopher R, Papathanassiu Adonia E, Green Shawn J
Cardiology, Hypertension Institute at Saint Thomas West Hospital, Nashville, USA.
Nutrition, Calroy Health Sciences, Greensboro, USA.
Cureus. 2023 Sep 16;15(9):e45369. doi: 10.7759/cureus.45369. eCollection 2023 Sep.
The conversion of dietary inorganic nitrate (NO3-) to nitric oxide (NO) is a non-canonical pathway that plays an important role in NO biology, especially under pathological conditions. Inorganic NO3- supplementation is a proven method for controlling mild hypertension. Recent reports have suggested that another gaseous transmitter, hydrogen sulfide (H2S), influences NO biosynthesis and metabolism. Here, data are presented from an open-label clinical trial examining the effect of an encapsulated formulation (Vascanox® HP) that combines dietary sources of inorganic NO3- and S-allylcysteine (SAC), a source of H2S from garlic, on NO bioavailability and blood pressure in subjects experiencing elevated blood pressure or mild hypertension.
An open-label clinical trial was conducted among patients with hypertension. Participants took Vascanox® for four weeks. Blood pressure was measured at baseline, two weeks, and four weeks. Salivary nitrite (NO2-), a surrogate of NO bioavailability, and NO3- were assessed prior to and two, six, and 24 hours after dosing on the first day of the study and prior to and two hours after dosing at subsequent study visits using saliva NO test strips. Changes in study outcomes over time were evaluated via analysis of variance (ANOVA) and paired t-tests.
Twelve participants completed the clinical trial. Vascanox® HP decreased systolic blood pressure by ~11 mmHg (p < 0.001) at two weeks and persisted beyond four weeks with daily supplementation. It also decreased the diastolic blood pressure of hypertensive subjects but not normotensive ones. The magnitude of the decrease was 11 mmHg (p < 0.01) at four weeks of study. Measurements of salivary concentrations of NO2- revealed high peak levels (743 uM) at two hours post-administration and a slow decay to elevated levels (348 uM) at 24 hours. NO2- salivary concentrations, a surrogate biomarker of NO bioavailability, remained above baseline for the duration of the study.
Vascanox® HP was shown to be a safe, effective, quick-acting, and long-lasting dietary supplement for controlling mild hypertension.
膳食无机硝酸盐（NO3-）向一氧化氮（NO）的转化是一条非经典途径，在NO生物学中发挥着重要作用，尤其是在病理条件下。补充无机NO3-是控制轻度高血压的一种已证实的方法。最近的报告表明，另一种气体递质硫化氢（H2S）会影响NO的生物合成和代谢。本文展示了一项开放标签临床试验的数据，该试验研究了一种胶囊制剂（Vascanox® HP）对血压升高或患有轻度高血压的受试者的NO生物利用度和血压的影响，该制剂结合了膳食来源的无机NO3-和S-烯丙基半胱氨酸（SAC，大蒜中的一种H2S来源）。
在高血压患者中进行了一项开放标签临床试验。参与者服用Vascanox®四周。在基线、两周和四周时测量血压。在研究第一天给药前、给药后两小时、六小时和24小时，以及在后续研究访视给药前和给药后两小时，使用唾液NO试纸评估唾液亚硝酸盐（NO2-，NO生物利用度的替代指标）和NO3-。通过方差分析（ANOVA）和配对t检验评估研究结果随时间的变化。
12名参与者完成了临床试验。Vascanox® HP在两周时使收缩压降低了约11 mmHg（p < 0.001），并且在每日补充超过四周后仍持续有效。它还降低了高血压受试者的舒张压，但对血压正常者没有影响。在研究四周时，舒张压降低幅度为11 mmHg（p < 0.01）。唾液中NO2-浓度的测量显示，给药后两小时出现高峰水平（743 μM），并在24小时缓慢下降至升高水平（348 μM）。在研究期间，作为NO生物利用度替代生物标志物的唾液NO2-浓度一直高于基线水平。
Vascanox® HP被证明是一种安全、有效、速效且持久的用于控制轻度高血压的膳食补充剂。
